Sheffield ECMC is pleased to announce the opening of the CARBON study, which is a randomised phase IB/IIA study of CApecitabine plus Radium-223 in breast cancer patients with BONe metastases. This academic study is funded by Bayer, and led by Professor Rob Coleman and Professor Janet Brown of the Sheffield ECMC. It is the first study to assess radium-223 with chemotherapy in advanced breast cancer.
We are pleased to announce that the ECMC Secretariat has undergone a name change and will now be referred to as the ECMC Programme Office. This is to reflect the added functionality that the Programme Office will have moving forward, including more proactive engagement with industry to enhance delivery and performance across the ECMC Network.
In addition, the ECMC Combinations Alliance team – Lyndall, Cathy, Julie, Zoe and Amy – have joined forces to sit within the newly-formed ECMC Programme Office team.
More and more people are being diagnosed with cancer each day, and up to 1 in 8 women will be diagnosed with breast cancer during their lifetime. Whilst treatments for breast cancer have advanced greatly over the years there is still an unmet clinical need for patients diagnosed with late stage metastatic cancer with only approximately 8% of patients surviving for more than 5 years following diagnosis.
Understanding patient tolerability in early clinical trials is a key aspect of drug development. New innovative research on PROACT (Patient Reported Opinions About clinical Tolerability), investigating the use of patient focused technology has been shared more widely through a recent research article.
The Cancer Centre at Guy’s will open to the public in September 2016 after many years of planning and design. Hospital staff and patients have worked side by side with architects to create it. The centre combines a caring environment with the latest scientific advances to provide the best possible treatment to people who have been diagnosed with cancer.
The DI-B4 Phase I trial of anti-CD19 monoclonal antibody for patients with advanced CD19-positive indolent B-cell malignancies (led by Chief Investigator Andrew Davies at Southampton ECMC) finished recruiting in July. The aim of the trial was to establish the biological effects and maximum tolerated dose of the low-fuscosylated anti-CD19 IgG1 monoclonal antibody DI-B4.
Scientists at Edinburgh-Dundee ECMC have uncovered important information about how ovarian cancer becomes resistant to certain treatments.
The researchers, based in Dundee, discovered that a gene called ABCB1, which is known to play a role in resistance to the chemotherapy drug paclitaxel in ovarian cancers, also causes resistance to other ovarian cancer treatments.